Earnings Preview: What To Expect From Vertex Pharmaceuticals' Report

With a market cap of $104.6 billion, Vertex Pharmaceuticals Incorporated (VRTX) is a biotechnology company focused on discovering, developing, and commercializing transformative therapies for serious diseases, with a primary focus on cystic fibrosis (CF). The company also advances treatments for sickle cell disease, beta thalassemia, APOL1-mediated kidney disease, type 1 diabetes, and other conditions. The Boston, Massachusetts-based company is slated to announce its fiscal Q3 2025 results after the marke ...